Abstract
ABSTRACTBackgroundAl-guided mapping establishes relationship between gene-signature and phenotype. Since, Immunomodulatory & antimicrobial molecules, both show anticancer as well as their relation with lipid; therefore, can be further used for cross-validation or enrichment analysis for early detection of cancer. Considering the information, a study was performed on the influence of Immunomodulatory and antimicrobial molecules on blood lipid profile at the early stage of cancer.Materials and MethodPresent study established a relationship between small molecule-vs-genotype to phenotype. Genotypic features extracted through RNAseq analysis for stomach adenocarcinoma, which was further mapped with blood lipid profile. RNA-seq expression, from a population, was collected as gene expression profile of transcriptome. Gene signature was identified through in-house processing. Blood lipid profile was as: Total Cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, Non-HDL-C, and TG to HDL ratio.ResultsTo evaluate the Immunomodulatory and antimicrobial molecules for anticancer activity in terms of their influence on blood lipid-profile, computational models were established for developing relationships between small molecules-vs-genotype. Immunomodulatory and antimicrobial activity showed significant impact on genotypic expression at cancerous conditions.ConclusionIt was concluded that usage of Immunomodulatory small molecules & antibiotics showed their impact on blood lipid profile. These results may support cross-checking the possibility of cancer during the early detection of cancer. Furthermore, suggested the use of immunomodulatory and antimicrobial small molecules for cross evaluation of early disease prediction of different cancer types.
Publisher
Cold Spring Harbor Laboratory